Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601)
China
· Delayed Price · Currency is CNY 16.20
+0.12 (0.75%)
Jan 6, 2025, 3:04 PM CST
Shenzhen Kangtai Biological Products Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 515.35 | 861.3 | -132.71 | 1,263 | 679.19 | 574.51 | Upgrade
|
| Depreciation & Amortization | 195.34 | 195.34 | 200.95 | 404.71 | 92.93 | 82.98 | Upgrade
|
| Other Amortization | 45.37 | 45.37 | 28.1 | 28.35 | 13.56 | 1.31 | Upgrade
|
| Loss (Gain) From Sale of Assets | 1.35 | 1.35 | -0.13 | -0.03 | 0.29 | 0.19 | Upgrade
|
| Asset Writedown & Restructuring Costs | 3.32 | 3.32 | 624.09 | 3.41 | 9.63 | 1.48 | Upgrade
|
| Loss (Gain) From Sale of Investments | -1.89 | -1.89 | -4.12 | -29.71 | -43.82 | -6.99 | Upgrade
|
| Provision & Write-off of Bad Debts | 12.49 | 12.49 | 39.64 | 10.45 | 20.32 | 4.1 | Upgrade
|
| Other Operating Activities | 186.06 | 229.67 | 384.44 | 217.36 | 2.54 | 8.92 | Upgrade
|
| Change in Accounts Receivable | -417.18 | -417.18 | -488.76 | 273.88 | -796.49 | -178.33 | Upgrade
|
| Change in Inventory | 8.68 | 8.68 | 220.75 | -746.67 | -209.73 | -31.9 | Upgrade
|
| Change in Accounts Payable | 18.89 | 18.89 | -130.98 | 146.54 | 451.25 | -102.85 | Upgrade
|
| Change in Other Net Operating Assets | -3.19 | -3.19 | 9.97 | 29.95 | 126.95 | 131.89 | Upgrade
|
| Operating Cash Flow | 643.54 | 1,033 | 545.7 | 1,652 | 439.85 | 505.7 | Upgrade
|
| Operating Cash Flow Growth | -29.33% | 89.32% | -66.97% | 275.65% | -13.02% | 50.29% | Upgrade
|
| Capital Expenditures | -568.26 | -718.45 | -1,310 | -2,540 | -1,227 | -386.63 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.93 | 0.96 | 0.08 | 0.19 | 1.02 | 0.24 | Upgrade
|
| Investment in Securities | -129.4 | 218 | -1,338 | 1,037 | -2,625 | - | Upgrade
|
| Other Investing Activities | 81.2 | 60.62 | 42.01 | 63.2 | 13.73 | 6.68 | Upgrade
|
| Investing Cash Flow | -615.52 | -438.87 | -2,606 | -1,440 | -3,837 | -379.7 | Upgrade
|
| Long-Term Debt Issued | - | 379.91 | 529.46 | 3,141 | 91.11 | 20 | Upgrade
|
| Long-Term Debt Repaid | - | -299.43 | -1,070 | -26.48 | -256.02 | -68.84 | Upgrade
|
| Net Debt Issued (Repaid) | -389.72 | 80.48 | -540.98 | 3,115 | -164.91 | -48.84 | Upgrade
|
| Issuance of Common Stock | - | - | 587.29 | 164.74 | 3,519 | - | Upgrade
|
| Repurchase of Common Stock | -100.99 | -100.99 | -20.55 | - | -0.21 | - | Upgrade
|
| Common Dividends Paid | -461.16 | -237.23 | -622.15 | -220.42 | -207.32 | -178.07 | Upgrade
|
| Other Financing Activities | 87.56 | -160.31 | 131.52 | -607.18 | 632.17 | 0.18 | Upgrade
|
| Financing Cash Flow | -864.32 | -418.05 | -464.88 | 2,452 | 3,779 | -226.74 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.2 | 0.04 | -1.66 | -0.98 | -0.04 | 0.01 | Upgrade
|
| Net Cash Flow | -836.51 | 176.22 | -2,527 | 2,663 | 381.61 | -100.73 | Upgrade
|
| Free Cash Flow | 75.28 | 314.65 | -764.7 | -888.15 | -786.81 | 119.07 | Upgrade
|
| Free Cash Flow Growth | -37.59% | - | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | 2.48% | 9.05% | -24.22% | -24.32% | -34.80% | 6.13% | Upgrade
|
| Free Cash Flow Per Share | 0.07 | 0.28 | -0.69 | -0.80 | -0.73 | 0.12 | Upgrade
|
| Cash Income Tax Paid | 114.12 | 85.74 | 185.63 | 38.68 | 149.75 | 171.42 | Upgrade
|
| Levered Free Cash Flow | -1,320 | 81.42 | -887.61 | -1,972 | -650.92 | -127.55 | Upgrade
|
| Unlevered Free Cash Flow | -1,243 | 152.49 | -819.5 | -1,938 | -649.46 | -121.96 | Upgrade
|
| Change in Net Working Capital | 1,150 | -140.62 | -128.91 | 673.43 | 60.38 | 333.06 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.